trial

Effect of Fluvoxamine on Cognition, Behavior, Symptoms and mRNA and Protein Expression in Schizophrenia Patients

NCTId NCT01832285
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Unknown
Enrollment 40 (estimated)
Sponsored by Sha'ar Menashe Mental Health Center
Primary completion 2013-10
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Unknown
Enrollment
40 (estimated)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2012-12
Primary completion
2013-10
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Fluvoxamine

Sponsors

Sha'ar Menashe Mental Health CenterLead Sponsor

Investigators

1
Silver Henry, ProfessorPrincipal Investigator

Sites

1 total
Hadera, Israel

Facts & assertions

4 sourced
Enrollment
40
Phase
NA
Primary Completion Date
2013-10
Status
UNKNOWN
relationships
The graph out of here
drug
Fluvoxamine
drug
lead_sponsor
Sha'ar Menashe Mental Health Center
company
indication
Schizophrenia
indication
SCHIZOPHRENIA 1 (Disorder)
indication
investigator
Silver Henry, Professor
person